How much bigger will it be after the growth hormone treatment...LG Chem Develops AI Model for Forecasting Height Growth
May 28, 2025
|
LG Chem said it held a poster presentation at the European Society for Pediatric Endocrinology and the European Society for Endocrinology held in Copenhagen, Denmark, under the theme of 'Development of AI-based Growth Prediction Model'. The study was conducted with the participation of Professor Shim Young-seok of Ajou University Hospital and Jeong Ji-yeon of LG Chem's DX team.
Professor Shim Young-seok said in a presentation that `The demand at the clinic to anticipate the effects of growth hormone treatment on children with hypotension continues to growThe key growth prediction AI model was advanced by utilizing large-scale treatment data accumulated through LG Chem's Uropin Long-Term Safety Study."
LG Chem built an ensemble AI model that combines and recombines several existing deep learning models, learned the treatment data of 3045 children with low kidney disease (Trainings Dataset), including growth hormone deficiency, idiopathic hypodystrophy, unreasonable light weight, and Turner syndrome (girl), and used the actual growth value of 550 children (Test Dataset) as AI performance verification data to evaluate the stability of predicting the first to third years of treatment.
A comparison of traditional statistical technique models and growth prediction results for performance evaluation of AI-based models confirmed more accurate prediction performance in AI models. In particular, only the first medical measurements (height, weight, prescription dose of growth hormone drugs, etc.) in the AI-based model predicted the growth in the first year of treatment with an average error of 1.95 cm.
LG Chem plans to further stabilize the predictive performance and promote the application of the medical field to be a useful treatment method that presents changes in the kidney percentile according to the treatment of growth hormone drugs.
Meanwhile, LG Chem has been conducting 'LG Growth Study (LGS)' since 2012 to secure long-term growth hormone administration data for Korean children for the first time in Korea. LGS is a large-scale project that recruits 10,000 children for 20 years until 2032 to observe long-term safety and effectiveness.
Yoon Soo-young, in charge of life science and management innovation at LG Chem, said, `It is significant that we have developed a growth prediction model specialized for Korean children focusing on data on children with hypodermic diseases in Korea. We expect that LG Chem's customer value innovation performance will serve as a compass for treatment in the actual medical field.'
This article was translated by Naver AI translator.
